Intravesical chemotherapy for bladder cancer is unreliable and is also limited by incomplete drug delivery and poor compliance. A new urinary drug–disposing approach was developed to improve treatment outcomes by covering the entire urinary system, prolonging exposure of the tumor to drugs, and employing intravenous administration. For details, see the article by Bellat and colleagues on page 1409.